Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S Reaffirms FY 2013 Guidance-Conference Call


Monday, 11 Feb 2013 02:00am EST 

Novo Nordisk A/S announced that for fiscal 2013, it expects sales growth of 8% to 11% and an operating profit growth of around 10%. The Company reported revenue of DKK 78.026 billion and operating profit of DKK 29.474 billion for fiscal 2012. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of DKK 84.306 billion and operating profit of DKK 30.902 billion for fiscal 2013. 

Company Quote

48.29
0.54 +1.13%
11:14am EDT